BRAF mutations in non-small cell lung cancer: has finally Janus opened the door?-Reference-Cited by-同舟云学术

BRAF mutations in non-small cell lung cancer: has finally Janus opened the door?

Published:2016-05 Issue: Volume:101 Page:32-39
ISSN:1040-8428
Container-title:Critical Reviews in Oncology/Hematology
language:en
Short-container-title:Critical Reviews in Oncology/Hematology

Author:

Caparica Rafael,de Castro Gilberto,Gil-Bazo Ignacio,Caglevic Christian,Calogero Raffaele,Giallombardo Marco,Santos Edgardo S.,Raez Luis E.,Rolfo Christian

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference57 articles.

1. Raf: a strategic target for therapeutic development against cancer;Beeram;J. Clin. Oncol.,2005

2. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer;Brahmer;N. Engl. J. Med.,2012

3. Survival and long-term follow-up of the phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with previously treated advanced non-small cell lung cancer (NSCLC);Brahmer;J. Clin. Oncol.,2013

4. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer;Brahmer;N. Engl. J. Med.,2015

5. The impact of genomic changes on treatment of lung cancer;Cardarella;Am. J. Respir. Crit. Care Med.,2013

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combined SERS Microfluidic Chip with Gold Nanocone Array for Effective Early Lung Cancer Prognosis in Mice Model;International Journal of Nanomedicine;2023-06

2. Non‐small cell lung cancer in China;Cancer Communications;2022-09-08

3. BRAF-Mutated Non-Small Cell Lung Cancer: Current Treatment Status and Future Perspective;Frontiers in Oncology;2022-03-31

4. Drug resistance to targeted therapeutic strategies in non-small cell lung cancer;Pharmacology & Therapeutics;2020-02

5. Oncology—Acquired;Self-Assessment Questions for Clinical Molecular Genetics;2019